PLX-R18 has shown potential promise in significantly improving survival and accelerating recovery from H-ARS in preclinical animal and human studies, conducted with support from leading global health ...

Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as a Medical Countermeasure and for the treatment of Acute Respiratory Distress Syndrome (ARDS), ...

Pluri (PLUR) announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation syndrome, H-ARS, ...

Bolder BioTechnology, Inc. announced today that the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to fund the second year of ...

Lung cancer is the third most common type of cancer diagnosed in the United States but is the deadliest cancer in our country ...

How long could a person endure life during a deep-space voyage? And in the worst-case scenario, what would happen if someone ...

By slicing and dicing a dataset from 277 million patients at 1,591 hospitals, Epic publishes findings more quickly than ...

Varipulse blends the Carto 3 system, Johnson & Johnson's 3D cardiac mapping technology, with pulsed-field ablation treatment ... echocardiography to lower radiation exposure for patients and ...

Blood cancer cases are rising alarmingly among young Indians, with leukemia incidences increasing and bone marrow transplants ...

An international research team, led by the University of Wollongong (UOW), has found wearable organic X-ray sensors could ...

GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as a Medical Countermeasure and for the treatment of Acute ...